Diabetes is a complex disease characterized by hyperglycemia, together with polyuria, polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic, environmental, or immune dysfunction factors leading to pancreatic β-cell destruction depriving the organism from endogenous insulin, Type 2 diabetes mellitus (T2DM) is characterized by peripheral insulin resistance. Depending on the type of diabetes mellitus and drug mechanism to study, the animal model should be carefully selected among the wide variety of the currently available ones. This review discusses the most common animal models currently employed to study T1DM and T2DM. Moreover, an overview on the administration routes that could be used is also discussed.

Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II / Vieira, Raquel; Souto, Selma B; Sánchez-López, Elena; Machado, Ana López; Severino, Patricia; Jose, Sajan; Santini, Antonello; Silva, Amelia M; Fortuna, Ana; García, Maria Luisa; Souto, Eliana B. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 8:9(2019), p. 1332. [10.3390/jcm8091332]

Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II

Santini, Antonello
;
2019

Abstract

Diabetes is a complex disease characterized by hyperglycemia, together with polyuria, polydipsia, and polyphagia. While Type 1 diabetes mellitus (T1DM) results from genetic, environmental, or immune dysfunction factors leading to pancreatic β-cell destruction depriving the organism from endogenous insulin, Type 2 diabetes mellitus (T2DM) is characterized by peripheral insulin resistance. Depending on the type of diabetes mellitus and drug mechanism to study, the animal model should be carefully selected among the wide variety of the currently available ones. This review discusses the most common animal models currently employed to study T1DM and T2DM. Moreover, an overview on the administration routes that could be used is also discussed.
2019
Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome-Strategies for In Vivo Administration: Part-II / Vieira, Raquel; Souto, Selma B; Sánchez-López, Elena; Machado, Ana López; Severino, Patricia; Jose, Sajan; Santini, Antonello; Silva, Amelia M; Fortuna, Ana; García, Maria Luisa; Souto, Eliana B. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 8:9(2019), p. 1332. [10.3390/jcm8091332]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/773807
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 65
  • ???jsp.display-item.citation.isi??? 50
social impact